nach oben

Cancer Microenvironment

Erschienen in:

01.12.2015 | Original Article

Stroma as an Active Player in the Development of the Tumor Microenvironment

verfasst von: L. Vannucci

Erschienen in: Cancer Microenvironment | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The stroma is a considerable part of the tumor microenvironment. Because of its complexity, it can influence both cancer and immune cells in their behavior and cross-talk. Aside from soluble products released by non-cancer and cancer cells, extracellular matrix components have been increasingly recognized as more than just minor players in the constitution, development and regulation of the tumor microenvironment. The variations in the connective scaffold architecture, induced by transforming growth factor beta, lysyl oxidase and metalloproteinase activity, create different conditions of ECM density and stiffness. They exert broad effects on immune cells (e.g. physical barriers, modulation by release of stored TGF-β1), mesenchymal cells (transition to myofibroblasts), epithelial cells (epithelial-to-mesenchymal transition), cancer cells (progression to metastatic phenotype) and stem cells (activation of differentiation addressed by the microenvironment characteristics). Physiological mechanisms of the wound healing process, as well as mechanisms of fibrosis in some chronic pathologies, closely recall aspects of cancer deregulated biology. Their elucidation can provide a better understanding of tumor microenvironment immunobiology. In the following short review, we will focus on some aspects of the fibrous stroma to highlight its active participation in the tumor microenvironment constitution, tumor progression and the local immunological network.

Pietras K, Ostman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316:1324–1331PubMedCrossRef

Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean MC (2011) Tumor microenvironment is multifaceted. Cancer Metastasis Rev 30:13–25PubMedCrossRef

Wu Y, Antony S, Meitzler JL, Doroshow JH (2013) Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett 345:164–173

Taipale J, Miyazono K, Heldin CH, Keski-Oja J (1994) Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 124:171–181PubMedCrossRef

Unsöld C, Hyytiäinen M, Bruckner-Tuderman L, Keski-Oja J (2001) Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 114:187–197PubMed

Valenick LV, Hsia HC, Schwarzbauer JE (2005) Fibronectin fragmentation promotes alpha4beta1 integrin-mediated contraction of a fibrin-fibronectin provisional matrix. Exp Cell Res 309:48–55PubMedCrossRef

Wipff PJ, Hinz B (2008) Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur J Cell Biol 87:601–615PubMedCrossRef

Monboisse JC, Oudart JB, Ramont L, Brassart-Pasco S, Maquart FX (2014) Matrikines from basement membrane collagens: A new anti-cancer strategy. Biochim Biophys Acta 1840:2589-2598

Egeblad M, Rasch MG, Weaver VM (2010) Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 22:697–706PubMedPubMedCentralCrossRef

10.

Friedl P, Bröcker EB, Zänker KS (1998) Integrins, cell matrix interactions and cell migration strategies: fundamental differences in leukocytes and tumor cells. Cell Adhes Commun 6:225–236PubMedCrossRef

11.

Friedl P, Bröcker EB (2000) T cell migration in three-dimensional extracellular matrix: guidance by polarity and sensations. Dev Immunol 7:249–266PubMedPubMedCentralCrossRef

12.

Miles FL, Sikes RA (2014) Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 12:297–312PubMedPubMedCentralCrossRef

13.

Peranzoni E, Rivas-Caicedo A, Bougherara H, Salmon H, Donnadieu E (2013) Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Mol Life Sci 70:4431–4448PubMedCrossRef

14.

Dvorak HF (1986) Tumors: wounds that do not heal. N Engl J Med 315:1650–1659PubMedCrossRef

15.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef

16.

Cassetta L, Cassol E, Poli G (2011) Macrophage polarization in health and disease. Sci World J 11:2391–2402CrossRef

17.

Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229:176–185PubMedCrossRef

18.

Davies LC, Jenkins SJ, Allen JE, Taylor PR (2013) Tissue-resident macrophages. Nat Immunol 14:986–995PubMedPubMedCentralCrossRef

19.

Chambers SE, O’Neill CL, O’Doherty TM, Medina RJ, Stitt AW (2013) The role of immune-related myeloid cells in angiogenesis. Immunobiology 218:1370–1375PubMedCrossRef

20.

Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262–274PubMedCrossRef

21.

Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG (2007) Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56:1687–1700PubMedCrossRef

22.

Weidenbusch M, Anders HJ (2012) Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis. J Innate Immun 4:463–477PubMedCrossRef

23.

Mantovani A (2012) MSCs, macrophages, and cancer: a dangerous ménage-à-trois. Cell Stem Cell 11:730–732PubMedCrossRef

24.

Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A (2013) Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 228:1404–1412PubMedCrossRef

25.

Li B, Wang JH (2011) Fibroblasts and myofibroblasts in wound healing: force generation and measurement. J Tissue Viability 20:108–120PubMedPubMedCentralCrossRef

26.

Polanska UM, Orimo A (2013) Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 228:1651–1657PubMedCrossRef

27.

Byun JS, Gardner K (2013) Wounds that will not heal: pervasive cellular reprogramming in cancer. Am J Pathol 182:1055–1064PubMedPubMedCentralCrossRef

28.

Liguori M, Solinas G, Germano G, Mantovani A, Allavena P (2011) Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel) 3:3740–3761CrossRef

29.

Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83:1136–1144PubMedCrossRef

30.

Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, Abutbul S, Huszar M, Dinarello CA, Apte RN, Voronov E (2013) The role of IL-1β in the early tumor cell-induced angiogenic response. J Immunol 190:3500–3509PubMedCrossRef

31.

Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39:1003–1018PubMedPubMedCentralCrossRef

32.

Rider P, Carmi Y, Voronov E, Apte RN (2013) Interleukin-1α. Semin Immunol 25:430–438PubMedCrossRef

33.

Perrot CY, Javelaud D, Mauviel A (2013) Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma. Ann Dermatol 25:135–144PubMedPubMedCentralCrossRef

34.

Jakowlew SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25:435–457PubMedCrossRef

35.

Petrella BL, Vincenti MP (2012) Interleukin-1β mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein β. Cancer Med 1:17–27PubMedPubMedCentralCrossRef

36.

Yan C, Boyd DD (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211:19–26PubMedCrossRef

37.

Oka M, Iwata C, Suzuki HI, Kiyono K, Morishita Y, Watabe T, Komuro A, Kano MR, Miyazono K (2008) Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 111:4571–4579PubMedCrossRef

38.

Wong SF, Lai LC (2001) The role of TGFbeta in human cancers. Pathology 33:85–92PubMedCrossRef

39.

Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S (2012) TGF-β - an excellent servant but a bad master. J Transl Med 10:183PubMedPubMedCentralCrossRef

40.

Pickup M, Novitskiy S, Moses HL (2013) The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13(11):788–799PubMedPubMedCentralCrossRef

41.

Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, Hattori R, Matsukawa Y, Mizuno T, Noda Y, Nishimura H, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y (2013) TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol 24:1627–1642PubMedPubMedCentralCrossRef

42.

Clavin NW, Avraham T, Fernandez J, Daluvoy SV, Soares MA, Chaudhry A, Mehrara BJ (2008) TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am J Physiol Heart Circ Physiol 295:H2113–H2127PubMedCrossRef

43.

Ji RC (2006) Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 25:677–694PubMedCrossRef

44.

Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4 + CD25- T cells into CD4 + CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883–2892PubMedCrossRef

45.

Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM, Huang RP (2014) Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845:182–201

46.

Horiguchi M, Ota M, Rifkin DB (2012) Matrix control of transforming growth factor-β function. J Biochem 152:321–329PubMedPubMedCentralCrossRef

47.

Taipale J, Saharinen J, Keski-Oja J (1998) Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res 75:87–134PubMedCrossRef

48.

Shahinian H, Loessner D, Biniossek ML, Kizhakkedathu JN, Clements JA, Magdolen V, Schilling O (2014) Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells. Mol Oncol 8:68–82

49.

Xiao Q, Ge G (2012) Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron 5:261–273PubMedPubMedCentralCrossRef

50.

Kim YM, Kim EC, Kim Y (2011) The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 38:145–149PubMedCrossRef

51.

Cano A, Santamaría PG, Moreno-Bueno G (2012) LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol 8:1095–1108PubMedCrossRef

52.

Zaffryar-Eilot S, Marshall D, Voloshin T, Bar-Zion A, Spangler R, Kessler O, Ghermazien H, Brekhman V, Suss-Toby E, Adam D, Shaked Y, Smith V, Neufeld G (2013) Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours. Carcinogenesis 34:2370–2379PubMedCrossRef

53.

Barker HE, Bird D, Lang G, Erler JT (2013) Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. Mol Cancer Res 11:1425–1436PubMedCrossRef

54.

Sion AM, Figg WD (2006) Lysyl oxidase (LOX) and hypoxia-induced metastases. Cancer Biol Ther 5:909–911PubMedCrossRef

55.

Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL (2013) Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res 73:5336–5346PubMedPubMedCentralCrossRef

56.

Leask A, Hutchenreuther J (2014) Activation of latent TGFβ by α(v)β (1) integrin: of potential importance in myofibroblast activation in fibrosis. J Cell Commun Signal 8:171–172

57.

Wipff PJ, Rifkin DB, Meister JJ, Hinz B (2007) Myofibroblast contraction activates latent TGF-β 1 from the extracellular matrix. J Cell Biol 179:1311–1323PubMedPubMedCentralCrossRef

58.

Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891–906PubMedPubMedCentralCrossRef

59.

Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3:349–363PubMedCrossRef

60.

Calon A, Tauriello DV, Batlle E (2014) TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 25:15–22

61.

Desmoulière A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12PubMedCrossRef

62.

Montesano R, Orci L (1988) Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci U S A 85:4894–4897PubMedPubMedCentralCrossRef

63.

Buscemi L, Ramonet D, Klingberg F, Formey A, Smith-Clerc J, Meister JJ, Hinz B (2011) The single-molecule mechanics of the latent TGF-β1 complex. Curr Biol 21:2046–2054PubMedCrossRef

64.

Scharenberg MA, Pippenger BE, Sack R, Zingg D, Ferralli J, Schenk S, Martin I, Chiquet-Ehrismann R (2014) TGF-β-induced differentiation into myofibroblasts involves specific regulation of two MKL1 isoforms. J Cell Sci 127:1079–1091

65.

Vi L, de Lasa C, DiGuglielmo GM, Dagnino L (2011) Integrin-linked kinase is required for TGF-β1 induction of dermal myofibroblast differentiation. J Investig Dermatol 131:586–593PubMedCrossRef

66.

Huang X, Yang N, Fiore VF, Barker TH, Sun Y, Morris SW, Ding Q, Thannickal VJ, Zhou Y (2012) Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 47:340–348PubMedPubMedCentralCrossRef

67.

Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, Ferron SR, Herault Y, Pavlovic G, Ferguson-Smith AC, Watt FM (2013) Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 504:277–281PubMedPubMedCentralCrossRef

68.

Baglole CJ, Ray DM, Bernstein SH, Feldon SE, Smith TJ, Sime PJ, Phipps RP (2006) More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Investig 35:297–325CrossRef

69.

Chien AJ, Conrad WH, Moon RT (2009) A Wnt survival guide: from flies to human disease. J Investig Dermatol 129:1614–1627PubMedPubMedCentralCrossRef

70.

Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149:1192–1205PubMedCrossRef

71.

Chen D, Jarrell A, Guo C, Lang R, Atit R (2012) Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. Development 139:1522–1533PubMedPubMedCentralCrossRef

72.

O’Reilly S (2014) Innate immunity in systemic sclerosis pathogenesis. Clin Sci (Lond) 126:329–337CrossRef

73.

Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J (2012) Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 64:2734–2745PubMedPubMedCentralCrossRef

74.

Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, Sonnylal S, de Crombrugghe B, Taketo MM, Distler O, Schett G, Distler JH (2012) β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 71:761–767PubMedPubMedCentralCrossRef

75.

Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149:1192–1205PubMedCrossRef

76.

Kato S, Hayakawa Y, Sakurai H, Saiki I, Yokoyama S (2014) Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B. Cancer Sci 105:281–289

77.

Díaz Prado SM, Medina Villaamil V, Aparicio Gallego G, Blanco Calvo M, López Cedrún JL, Sironvalle Soliva S, Valladares Ayerbes M, García Campelo R, Antón Aparicio LM (2009) Expression of Wnt gene family and frizzled receptors in head and neck squamous cell carcinomas. Virchows Arch 455:67–75PubMedCrossRef

78.

Qurrat-Ul-Ain, Seemab U, Nawaz S, Rashid S (2011) Integrative analyses of conserved WNT clusters and their co-operative behaviour in human breast cancer. Bioinformation 7:339–46PubMedPubMedCentralCrossRef

79.

Wend P, Runke S, Wend K, Anchondo B, Yesayan M, Jardon M, Hardie N, Loddenkemper C, Ulasov I, Lesniak MS, Wolsky R, Bentolila LA, Grant SG, Elashoff D, Lehr S, Latimer JJ, Bose S, Sattar H, Krum SA, Miranda-Carboni GA (2013) WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med 5:264–279PubMedPubMedCentralCrossRef

80.

Bochet L, Lehuédé C, Dauvillier S, Wang YY, Dirat B, Laurent V, Dray C, Guiet R, Maridonneau-Parini I, Le Gonidec S, Couderc B, Escourrou G, Valet P, Muller C (2013) Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res 73:5657–5668PubMedCrossRef

81.

Kakudo N, Kushida S, Suzuki K, Ogura T, Notodihardjo PV, Hara T, Kusumoto K (2012) Effects of transforming growth factor-beta1 on cell motility, collagen gel contraction, myofibroblastic differentiation, and extracellular matrix expression of human adipose-derived stem cell. Hum Cell 25:87–95PubMedCrossRef

82.

Baarsma HA, Spanjer AI, Haitsma G, Engelbertink LH, Meurs H, Jonker MR, Timens W, Postma DS, Kerstjens HA, Gosens R (2011) Activation of WNT/β-catenin signaling in pulmonary fibroblasts by TGF-β₁ is increased in chronic obstructive pulmonary disease. PLoS One 6:e25450PubMedPubMedCentralCrossRef

83.

van Dekken H, Wink JC, Vissers KJ, Franken PF (2007) Ruud Schouten W, J Hop WC, Kuipers EJ, Fodde R, Janneke van der Woude C. Wnt pathway-related gene expression during malignant progression in ulcerative colitis. Acta Histochem 109:266–272PubMedCrossRef

84.

Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler TM, Gopalan B, Stylianou E, Fiocchi C (2011) Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 179:2660–2673PubMedPubMedCentralCrossRef

85.

Blaauboer ME, Emson CL, Verschuren L, van Erk M, Turner SM, Everts V, Hanemaaijer R, Stoop R (2013) Novel combination of collagen dynamics analysis and transcriptional profiling reveals fibrosis-relevant genes and pathways. Matrix Biol 32:424–431PubMedCrossRef

86.

Shih YR, Tseng KF, Lai HY, Lin CH, Lee OK (2011) Matrix stiffness regulation of integrin-mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells. J Bone Miner Res 26:730–738PubMedCrossRef

87.

Lui C, Lee K, Nelson CM (2012) Matrix compliance and RhoA direct the differentiation of mammary progenitor cells. Biomech Model Mechanobiol 11:1241–1297PubMedPubMedCentralCrossRef

88.

Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, Sahai E (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15:637–646PubMedCrossRef

Titel: Stroma as an Active Player in the Development of the Tumor Microenvironment
verfasst von: L. Vannucci
Publikationsdatum: 01.12.2015
Verlag: Springer Netherlands
Erschienen in: Cancer Microenvironment / Ausgabe 3/2015
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-014-0150-x

Springer Medizin

Stroma as an Active Player in the Development of the Tumor Microenvironment

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

The Role of Mast Cells in Molding the Tumor Microenvironment

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment

Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV

Preface

IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer

Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie